KitoZyme, the privately held Belgium-based world leader in the production of vegetable chitosan and chitin-glucan, is very pleased to announce the appointment of François Blondel as the new chief executive officer of the company.
François Blondel, 49, was also appointed to the KitoZyme board of directors, effective November 30, 2012.
Prior to joining KitoZyme, François Blondel has gained broad experience in the management of innovation-driven companies. He started his career in the chemical and in the oil and gas sectors, with assignments both in the United States and in Europe. In 1999, he joined International Brachytherapy (IBt), a startup in the medical device sector focused on cancer treatment. He served as CEO, leading IBt, a Euronext stock listed company, from its R&D stage to a successful and well diversified international group, European leader in its sector. Today, he is also serving as a board member of Compagnie du Bois Sauvage (diversified holding company listed on Euronext), Sopartec (holding of UCL university spinoffs), Nanocyl (world leader in production of carbon nanotubes), and a number of other companies active in the technology sector.